Meiyu Fang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Meiyu Fang has a total of 315 co-authors. Here are the top co-authors by number of shared publications:
- Jun Cao
Department of Head and Neck and Rare Oncology, Hangzhou Institute of Medicine (HIM), Zhejiang Cancer Hospital, Chinese Academy of Sciences, Hangzhou, China
24 shared publications - Jun Guo
Peking University Cancer Hospital 1 Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Renal Cancer and Melanoma Beijing, China
18 shared publications - Jing Lin
Department of Medical Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital , Fuzhou
17 shared publications - Lili Mao
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Melanoma and Sarcoma, Peking University Cancer Hospital and Institute, Beijing, China
17 shared publications - Ling Chen
Department of Medical Oncology, Fujian Cancer Hospital, Fujian Medical University Cancer Hospital, Fuzhou, China
17 shared publications - Lu Si
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Melanoma and Sarcoma, Peking University Cancer Hospital and Institute, Beijing, China
17 shared publications
Latest Publications
- Open Access
- 8 October 2026
- Published by Springer Nature in BMC Women's Health
Prognostic factors and treatment outcomes in uterine leiomyosarcoma: a 24-year experience from a single center
- 8 October 2026
- Published by Springer Nature in BMC Women's Health
Open AccessPrognostic factors and treatment outcomes in uterine leiomyosarcoma: a 24-year experience from a single center
- 1 October 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (28) , 2690-2699
Becotatug Vedotin Combined With Pucotenlimab in Platinum- and Immunotherapy-Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma
PURPOSE: Patients with recurrent or metastatic nasopharyngeal carcinoma (R/M NPC) have limited therapeutic options after failing platinum and anti–PD-1/PD-L1 therapy. We investigated the efficacy and safety of an epidermal growth factor receptor (EGFR)–directed antibody-drug conjugate (ADC) becotatug vedotin (BV) combined with a PD-1 inhibitor pucotenlimab in this setting of patients. MATERIALS AND METHODS: Magic-C001 (ClinicalTrials.gov identifier: NCT05688605 ) is an ongoing, open-label, multicohort, dose escalation (phase I) and expansion (phase II) study in patients with EGFR-positive solid tumors. Eligible patients received pucotenlimab 3.0 mg/kg and BV at 1.8-2.3 mg/kg (phase I) or 2.0 mg/kg (phase II for NPC) once every 3 weeks. The primary end point for phase II was objective response rate (ORR). Secondary end points included duration of response (DoR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and safety. RESULTS: Among 31 patients with NPC at the recommended phase II dose (RP2D) from phase I and II who had received anti–PD-1/PD-L1 and platinum-based therapy, the confirmed ORR was 71.0% (95% CI, 52.0 to 85.8); DCR was 93.5% (95% CI, 78.6 to 99.2). The median DoR and PFS were 14.0 months (95% CI, 5.7 to not estimated) and 12.0 months (95% CI, 6.8 to 15.4), respectively. Median OS was not mature. Most common treatment-related adverse events (TRAEs) were pruritus (71.9%), hypoesthesia (65.6%), anemia (59.4%), and rash (56.3%). TRAEs of ≥grade 3 occurred in 40.6% of patients. No TRAEs led to death. CONCLUSION: To our knowledge, we report the first trial combining an ADC with immunotherapy for platinum and anti–PD-1/PD-L1–resistant NPC. BV plus pucotenlimab yielded a notable ORR with exceptionally durable responses and substantially prolonged PFS, alongside manageable toxicities. This regimen may offer a promising anti–PD-1 rechallenge strategy in this population, which is being confirmed in an ongoing, multicenter, randomized controlled, phase III study.
- 1 October 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (28) , 2690-2699
Becotatug Vedotin Combined With Pucotenlimab in Platinum- and Immunotherapy-Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma
PURPOSE: Patients with recurrent or metastatic nasopharyngeal carcinoma (R/M NPC) have limited therapeutic options after failing platinum and anti–PD-1/PD-L1 therapy. We investigated the efficacy and safety of an epidermal growth factor receptor (EGFR)–directed antibody-drug conjugate (ADC) becotatug vedotin (BV) combined with a PD-1 inhibitor pucotenlimab in this setting of patients. MATERIALS AND METHODS: Magic-C001 (ClinicalTrials.gov identifier: NCT05688605 ) is an ongoing, open-label, multicohort, dose escalation (phase I) and expansion (phase II) study in patients with EGFR-positive solid tumors. Eligible patients received pucotenlimab 3.0 mg/kg and BV at 1.8-2.3 mg/kg (phase I) or 2.0 mg/kg (phase II for NPC) once every 3 weeks. The primary end point for phase II was objective response rate (ORR). Secondary end points included duration of response (DoR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and safety. RESULTS: Among 31 patients with NPC at the recommended phase II dose (RP2D) from phase I and II who had received anti–PD-1/PD-L1 and platinum-based therapy, the confirmed ORR was 71.0% (95% CI, 52.0 to 85.8); DCR was 93.5% (95% CI, 78.6 to 99.2). The median DoR and PFS were 14.0 months (95% CI, 5.7 to not estimated) and 12.0 months (95% CI, 6.8 to 15.4), respectively. Median OS was not mature. Most common treatment-related adverse events (TRAEs) were pruritus (71.9%), hypoesthesia (65.6%), anemia (59.4%), and rash (56.3%). TRAEs of ≥grade 3 occurred in 40.6% of patients. No TRAEs led to death. CONCLUSION: To our knowledge, we report the first trial combining an ADC with immunotherapy for platinum and anti–PD-1/PD-L1–resistant NPC. BV plus pucotenlimab yielded a notable ORR with exceptionally durable responses and substantially prolonged PFS, alongside manageable toxicities. This regimen may offer a promising anti–PD-1 rechallenge strategy in this population, which is being confirmed in an ongoing, multicenter, randomized controlled, phase III study.
- Open Access
- 7 September 2026
- Published by Wiley in Cancer Medicine
- Vol. 15 (9) , e72272
Phase Ib Trial of Finotonlimab Combined With SCT200 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Background: Effective treatment options remain limited for patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC), including patients who have progressed after platinum‐based chemotherapy and systemic‐therapy‐naïve patients. This Phase Ib trial evaluates the efficacy and safety of finotonlimab, a PD‐1 antibody, combined with SCT200, an EGFR antibody. Methods: This prospective, multicenter, open‐label study enrolled patients into two cohorts: Cohort A (previously treated with platinum‐based chemotherapy and immune checkpoint inhibitors) and Cohort B (systemic therapy‐naïve). Patients received finotonlimab (200 mg every 3 weeks) and SCT200 (6 mg/kg weekly for 12 weeks, then 8 mg/kg every 2 weeks). The primary endpoint was objective response rate (ORR). Results: Among 41 patients, Cohort A ( n = 11) showed an ORR of 27.3%, median progression‐free survival (PFS) of 5.8 months, and median overall survival (OS) of 10.6 months. Cohort B ( n = 30) had an ORR of 56.7%, median PFS of 9.6 months, and an estimated median OS of 13.6 months. Common treatment‐related adverse events included hypomagnesemia (63.4%), rash (41.5%), and acneiform dermatitis (36.6%), which were manageable. Conclusions: The combination of finotonlimab and SCT200 demonstrates promising efficacy, particularly in systemic therapy‐naïve patients, warranting further investigation. Trial Registration: ClinicalTrials.gov identifier: NCT05552807; Chinadrugtrials.org.cn identifier: CTR20220917
- 7 September 2026
- Published by Wiley in Cancer Medicine
- Vol. 15 (9) , e72272
Open AccessPhase Ib Trial of Finotonlimab Combined With SCT200 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Background: Effective treatment options remain limited for patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC), including patients who have progressed after platinum‐based chemotherapy and systemic‐therapy‐naïve patients. This Phase Ib trial evaluates the efficacy and safety of finotonlimab, a PD‐1 antibody, combined with SCT200, an EGFR antibody. Methods: This prospective, multicenter, open‐label study enrolled patients into two cohorts: Cohort A (previously treated with platinum‐based chemotherapy and immune checkpoint inhibitors) and Cohort B (systemic therapy‐naïve). Patients received finotonlimab (200 mg every 3 weeks) and SCT200 (6 mg/kg weekly for 12 weeks, then 8 mg/kg every 2 weeks). The primary endpoint was objective response rate (ORR). Results: Among 41 patients, Cohort A ( n = 11) showed an ORR of 27.3%, median progression‐free survival (PFS) of 5.8 months, and median overall survival (OS) of 10.6 months. Cohort B ( n = 30) had an ORR of 56.7%, median PFS of 9.6 months, and an estimated median OS of 13.6 months. Common treatment‐related adverse events included hypomagnesemia (63.4%), rash (41.5%), and acneiform dermatitis (36.6%), which were manageable. Conclusions: The combination of finotonlimab and SCT200 demonstrates promising efficacy, particularly in systemic therapy‐naïve patients, warranting further investigation. Trial Registration: ClinicalTrials.gov identifier: NCT05552807; Chinadrugtrials.org.cn identifier: CTR20220917
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Data from Becotatug Vedotin in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: A Multicenter, Phase IIa Trial
Purpose:This multicenter, phase IIa trial (NCT04868162) investigated the efficacy and safety of becotatug vedotin, an anti–epidermal growth factor receptor (EGFR) antibody–drug conjugate, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) who have limited therapeutic options.Patients and Methods:Patients with R/M SCCHN who progressed after platinum-based chemotherapy and/or programmed cell death 1 (PD-1)/programmed death ligand 1 (PD-L1) inhibitors, including those with multiple lines of prior therapy, were administered intravenous becotatug vedotin at either 2 or 2.3 mg/kg every 3 weeks. The primary endpoint was the objective response rate (ORR).Results:Sixty-seven patients were enrolled (35 received 2 mg/kg and 32 received 2.3 mg/kg). The ORR was 20.9% [14/67, 95% confidence interval (CI), 11.9–32.6], with a median duration of response (DoR) of 10.9 months (95% CI, 2.6–15.1). The median progression-free survival (PFS) was 2.9 months (95% CI, 1.8–3.9), and the median overall survival (OS) was 6.7 months (95% CI, 5–8.9). Treatment-related adverse events (TRAE) were reported in 91% (61/67) patients, most commonly being rash (26.9%), pruritus (25.4%), constipation (23.9%), and anemia (20.9%).Conclusions:Becotatug vedotin demonstrated promising antitumor activity with a manageable safety profile in previously heavily treated R/M SCCHN, particularly at the recommended dose of 2.3 mg/kg, among patients who had failed platinum-based chemotherapy and PD-1/PD-L1 inhibitors (≤2 prior lines of therapy).
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Becotatug Vedotin in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: A Multicenter, Phase IIa Trial
Purpose:This multicenter, phase IIa trial (NCT04868162) investigated the efficacy and safety of becotatug vedotin, an anti–epidermal growth factor receptor (EGFR) antibody–drug conjugate, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) who have limited therapeutic options.Patients and Methods:Patients with R/M SCCHN who progressed after platinum-based chemotherapy and/or programmed cell death 1 (PD-1)/programmed death ligand 1 (PD-L1) inhibitors, including those with multiple lines of prior therapy, were administered intravenous becotatug vedotin at either 2 or 2.3 mg/kg every 3 weeks. The primary endpoint was the objective response rate (ORR).Results:Sixty-seven patients were enrolled (35 received 2 mg/kg and 32 received 2.3 mg/kg). The ORR was 20.9% [14/67, 95% confidence interval (CI), 11.9–32.6], with a median duration of response (DoR) of 10.9 months (95% CI, 2.6–15.1). The median progression-free survival (PFS) was 2.9 months (95% CI, 1.8–3.9), and the median overall survival (OS) was 6.7 months (95% CI, 5–8.9). Treatment-related adverse events (TRAE) were reported in 91% (61/67) patients, most commonly being rash (26.9%), pruritus (25.4%), constipation (23.9%), and anemia (20.9%).Conclusions:Becotatug vedotin demonstrated promising antitumor activity with a manageable safety profile in previously heavily treated R/M SCCHN, particularly at the recommended dose of 2.3 mg/kg, among patients who had failed platinum-based chemotherapy and PD-1/PD-L1 inhibitors (≤2 prior lines of therapy).
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Data 1 from Becotatug Vedotin in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: A Multicenter, Phase IIa Trial
Supplementary Methods, Supplementary Tables S1-6, Supplementary Figure S1
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data 1 from Becotatug Vedotin in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: A Multicenter, Phase IIa Trial
Supplementary Methods, Supplementary Tables S1-6, Supplementary Figure S1
- 23 February 2026
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 96 (1) , 19
Synergistic interactions and optimal sequencing of chemotherapy and immunotherapy in cancer treatment
Chemotherapy and immunotherapy are now both crucial methods for combating cancers. However, the interplay between immunotherapy and chemotherapy is highly intricate, and varying combinations and sequencing of treatment may produce distinct therapeutic outcomes. Chemotherapy, with its cytotoxic effect, may trigger immunogenic cell death and alter the tumor microenvironment, hence affecting immune responses. On the other hand, immunotherapy may potentially enhance the effectiveness of chemotherapy by eliminating cancer cells via the stimulation of the immune system. This article focuses on the effect of treatment sequence on efficacy, which is less systematically discussed in the current literature. We deeply analyzed the synergistic potential of chemotherapy and immunotherapy and explored how these two modalities can enhance each other to improve treatment efficacy. By summarizing the latest research results, we elucidated their interaction mechanisms and emphasized the potential advantages of sequential treatment. Integrating these insights aims to provide clinicians with novel therapeutic concepts, consequently optimizing therapy strategies and augmenting the prognosis for cancer patients. Graphical abstract 1 Created with BioRender.com. https://BioRender.com/nwnjr8c
- 23 February 2026
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 96 (1) , 19
Synergistic interactions and optimal sequencing of chemotherapy and immunotherapy in cancer treatment
Chemotherapy and immunotherapy are now both crucial methods for combating cancers. However, the interplay between immunotherapy and chemotherapy is highly intricate, and varying combinations and sequencing of treatment may produce distinct therapeutic outcomes. Chemotherapy, with its cytotoxic effect, may trigger immunogenic cell death and alter the tumor microenvironment, hence affecting immune responses. On the other hand, immunotherapy may potentially enhance the effectiveness of chemotherapy by eliminating cancer cells via the stimulation of the immune system. This article focuses on the effect of treatment sequence on efficacy, which is less systematically discussed in the current literature. We deeply analyzed the synergistic potential of chemotherapy and immunotherapy and explored how these two modalities can enhance each other to improve treatment efficacy. By summarizing the latest research results, we elucidated their interaction mechanisms and emphasized the potential advantages of sequential treatment. Integrating these insights aims to provide clinicians with novel therapeutic concepts, consequently optimizing therapy strategies and augmenting the prognosis for cancer patients. Graphical abstract 1 Created with BioRender.com. https://BioRender.com/nwnjr8c
- 28 January 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (8) , 1445-1453
Becotatug Vedotin in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: A Multicenter, Phase IIa Trial
Purpose: This multicenter, phase IIa trial (NCT04868162) investigated the efficacy and safety of becotatug vedotin, an anti–epidermal growth factor receptor (EGFR) antibody–drug conjugate, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) who have limited therapeutic options. Patients and Methods: Patients with R/M SCCHN who progressed after platinum-based chemotherapy and/or programmed cell death 1 (PD-1)/programmed death ligand 1 (PD-L1) inhibitors, including those with multiple lines of prior therapy, were administered intravenous becotatug vedotin at either 2 or 2.3 mg/kg every 3 weeks. The primary endpoint was the objective response rate (ORR). Results: Sixty-seven patients were enrolled (35 received 2 mg/kg and 32 received 2.3 mg/kg). The ORR was 20.9% [14/67, 95% confidence interval (CI), 11.9–32.6], with a median duration of response (DoR) of 10.9 months (95% CI, 2.6–15.1). The median progression-free survival (PFS) was 2.9 months (95% CI, 1.8–3.9), and the median overall survival (OS) was 6.7 months (95% CI, 5–8.9). Treatment-related adverse events (TRAE) were reported in 91% (61/67) patients, most commonly being rash (26.9%), pruritus (25.4%), constipation (23.9%), and anemia (20.9%). Conclusions: Becotatug vedotin demonstrated promising antitumor activity with a manageable safety profile in previously heavily treated R/M SCCHN, particularly at the recommended dose of 2.3 mg/kg, among patients who had failed platinum-based chemotherapy and PD-1/PD-L1 inhibitors (≤2 prior lines of therapy).
- 28 January 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (8) , 1445-1453
Becotatug Vedotin in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: A Multicenter, Phase IIa Trial
Purpose: This multicenter, phase IIa trial (NCT04868162) investigated the efficacy and safety of becotatug vedotin, an anti–epidermal growth factor receptor (EGFR) antibody–drug conjugate, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) who have limited therapeutic options. Patients and Methods: Patients with R/M SCCHN who progressed after platinum-based chemotherapy and/or programmed cell death 1 (PD-1)/programmed death ligand 1 (PD-L1) inhibitors, including those with multiple lines of prior therapy, were administered intravenous becotatug vedotin at either 2 or 2.3 mg/kg every 3 weeks. The primary endpoint was the objective response rate (ORR). Results: Sixty-seven patients were enrolled (35 received 2 mg/kg and 32 received 2.3 mg/kg). The ORR was 20.9% [14/67, 95% confidence interval (CI), 11.9–32.6], with a median duration of response (DoR) of 10.9 months (95% CI, 2.6–15.1). The median progression-free survival (PFS) was 2.9 months (95% CI, 1.8–3.9), and the median overall survival (OS) was 6.7 months (95% CI, 5–8.9). Treatment-related adverse events (TRAE) were reported in 91% (61/67) patients, most commonly being rash (26.9%), pruritus (25.4%), constipation (23.9%), and anemia (20.9%). Conclusions: Becotatug vedotin demonstrated promising antitumor activity with a manageable safety profile in previously heavily treated R/M SCCHN, particularly at the recommended dose of 2.3 mg/kg, among patients who had failed platinum-based chemotherapy and PD-1/PD-L1 inhibitors (≤2 prior lines of therapy).
- Open Access
- 7 January 2026
- Published by Wiley in Molecular Genetics & Genomic Medicine
- Vol. 14 (1) , e70177
Clinical Features and Treatment Strategies of Li‐Fraumeni Syndrome Patients With Inherited TP53 Mutations
Background: Li‐Fraumeni syndrome is a rare autosomal dominant disorder caused by a pathogenic mutation of the tumor suppressor gene TP53 . This disease starts at an early age and has been shown to be associated with multiple tumors. The study aims to discuss the clinical and genetic characteristics of Li‐Fraumeni syndrome (LFS) and to provide therapeutic experience of LFS. Materials and Methods: We conducted a retrospective analysis of the clinicopathologic features, family history, treatment and follow‐up in five LFS patients with germline TP53 (NCBI Gene: 7157 , HGNC: 11998 , OMIM: 191170 ) pathogenic/likely pathogenic (P/LP) variants. This research had been approved by the ethics committee and implemented. Results: Our study involved five LFS patients with germline TP53 P/LP variants, including thyroid cancer, ovarian melanoma, colon cancer, fibrosarcoma, and lung cancer. Among this group of patients, the age at which tumors first appeared was between 24 and 53 years old. Three patients had a family history of tumors, and the other two were probands in the family. Traditional chemotherapy has limited effectiveness in clinical practice and may increase the risk of tumor development. However, immune checkpoint inhibitors (ICIs) have shown unexpected efficacy in patients with high programmed cell death ligand‐1 (PD‐L1) expression. Next‐generation sequencing (NGS) and PD‐L1 detection may provide more potential targets for LFS patients to achieve better therapeutic outcomes. In addition, we have added a new TP53 frameshift mutation spectrum, namely c.642_643delTA (p.H214Qfs*7), which belongs to the pathogenic variant. This mutant has not been described in the existing literature. Conclusion: Patients with LFS may be potential beneficiaries of immune checkpoint inhibitors and targeted therapies.
- 7 January 2026
- Published by Wiley in Molecular Genetics & Genomic Medicine
- Vol. 14 (1) , e70177
Open AccessClinical Features and Treatment Strategies of Li‐Fraumeni Syndrome Patients With Inherited TP53 Mutations
Background: Li‐Fraumeni syndrome is a rare autosomal dominant disorder caused by a pathogenic mutation of the tumor suppressor gene TP53 . This disease starts at an early age and has been shown to be associated with multiple tumors. The study aims to discuss the clinical and genetic characteristics of Li‐Fraumeni syndrome (LFS) and to provide therapeutic experience of LFS. Materials and Methods: We conducted a retrospective analysis of the clinicopathologic features, family history, treatment and follow‐up in five LFS patients with germline TP53 (NCBI Gene: 7157 , HGNC: 11998 , OMIM: 191170 ) pathogenic/likely pathogenic (P/LP) variants. This research had been approved by the ethics committee and implemented. Results: Our study involved five LFS patients with germline TP53 P/LP variants, including thyroid cancer, ovarian melanoma, colon cancer, fibrosarcoma, and lung cancer. Among this group of patients, the age at which tumors first appeared was between 24 and 53 years old. Three patients had a family history of tumors, and the other two were probands in the family. Traditional chemotherapy has limited effectiveness in clinical practice and may increase the risk of tumor development. However, immune checkpoint inhibitors (ICIs) have shown unexpected efficacy in patients with high programmed cell death ligand‐1 (PD‐L1) expression. Next‐generation sequencing (NGS) and PD‐L1 detection may provide more potential targets for LFS patients to achieve better therapeutic outcomes. In addition, we have added a new TP53 frameshift mutation spectrum, namely c.642_643delTA (p.H214Qfs*7), which belongs to the pathogenic variant. This mutant has not been described in the existing literature. Conclusion: Patients with LFS may be potential beneficiaries of immune checkpoint inhibitors and targeted therapies.
- Open Access
- 26 November 2025
- Published by Springer Nature in Cardio-Oncology
- Vol. 11 (1) , 109
Clinical characteristics and treatment outcomes of primary cardiac sarcomas: a retrospective analysis
Primary cardiac sarcomas (PCSs) are uncommon malignant tumors with a poor prognosis. This study aims to present the clinical characteristics and treatment
- 26 November 2025
- Published by Springer Nature in Cardio-Oncology
- Vol. 11 (1) , 109
Open AccessClinical characteristics and treatment outcomes of primary cardiac sarcomas: a retrospective analysis
Primary cardiac sarcomas (PCSs) are uncommon malignant tumors with a poor prognosis. This study aims to present the clinical characteristics and treatment